Skip to main content
Oria Health
Updated October 2026
metabolic healthexercisemitochondria

MOTS-c

Mitochondrial-derived peptide · 16 amino acids

A mitochondrial-derived peptide encoded in mitochondrial DNA, studied for metabolic regulation and exercise mimicry effects.

MOTS-c
Evidence Grade
C
Trial Stage
Pre-clinical
C
Evidence Grade
Discovery
2015
Chang et al., Cell Metabolism
Amino Acids
16
mitochondrial-encoded
Biomarker Studies
14
plasma MOTS-c levels
Phase 1b
CB4211
NAFLD (modest results)
Side Effect Profile
Low
Moderate
Serious
Well-tolerated92%
Injection site reactions8%
Transient fatigue5%
Mild headache3%
Research Timeline
2001
Humanin discovered (first MDP)
2015
MOTS-c identified (Chang)
2016
Glucose metabolism studies
2020s
CB4211 Phase 1b trial
2023
Review articles published
Research In Progress·Full clinical analysis pending. Community notes and FAQ available below.

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA — making it one of the first mitochondrially derived peptides shown to have systemic hormonal effects. Discovered in 2015 by a team at the University of Southern California led by Pinchas Cohen, MOTS-c is essentially a hormone made by your mitochondria that tells the rest of your body how to handle fuel. Its levels decline with age, and researchers believe this decline contributes to age-related metabolic dysfunction. The name stands for Mitochondrial Open Reading Frame of the 12S rRNA-c — not catchy, but the biology is significant.

MOTS-c operates primarily through the AMPK (AMP-activated protein kinase) pathway, the cell's fuel gauge that activates when cellular energy is low. When MOTS-c activates AMPK, glucose uptake into cells increases, fatty acid oxidation ramps up, insulin sensitivity improves, and mitochondrial biogenesis is stimulated — cells produce more mitochondria, expanding their overall energy capacity. Under stress conditions, MOTS-c also translocates to the nucleus and regulates gene expression related to metabolic adaptation, suggesting a deeper role in how the body responds to exercise and caloric restriction. Crucially, glucose gets directed preferentially into muscle tissue rather than fat tissue, meaning more of what you eat fuels performance and less gets stored.

The subjective experience centers on endurance and sustained output rather than stimulant-like energy. The effects build over 2 to 4 weeks. Sets that previously left users gassed become manageable. Cardio sessions that were a grind become sustainable. Recovery between training sessions is faster. Injection site irritation is the most commonly reported side effect due to the peptide's mild acidity — using a 30g needle and injecting slowly reduces this significantly.

NUTRIENT INTAKEGLP-1 RELEASERECEPTOR ACTIVATIONINSULIN SECRETIONGLUCOSE UPTAKE

Community Experiences

"MOTS-c works. It is almost impossible to find failure when training lower weights for high reps. When hiking with friends I leave them in the dust." — r/Biohackers

"The effect is not about being stronger, it is about being able to sustain effort for longer. I push through sets where I would normally fail — not more force, just more endurance." — r/Biohackers

"Subtle compared to retatrutide. You don't feel a dramatic shift in the first few days. But at week three you realize the workouts are just easier, and recovery is noticeably faster." — r/Retatrutide

MOTS-c research

Mitochondrial-derived peptide research for metabolic optimization

Frequently Asked Questions

Is MOTS-c natural? Yes. MOTS-c is produced by your own mitochondria. Levels decline with age, and research is exploring whether restoring those levels can reverse age-related metabolic decline.

How long does MOTS-c take to work? Most researchers report noticeable effects within 2 to 4 weeks of consistent use. Endurance and energy benefits tend to appear before body composition changes.

What is the typical research dose? Research protocols commonly use 5 to 10 mg, administered 5 days per week. Some protocols extend to daily use.

Can MOTS-c help with weight loss? MOTS-c is not a direct weight loss peptide. It improves metabolic efficiency and exercise capacity, which supports weight loss when combined with a caloric deficit and physical activity. It is often stacked with appetite-suppressing peptides like retatrutide for a combined metabolic effect.

Stacking Suggestions

  • Retatrutide for combining appetite control with enhanced metabolic output during weight loss
  • SS-31 for direct mitochondrial membrane repair alongside MOTS-c's metabolic signaling
  • 5-Amino-1MQ for additional metabolic acceleration through a different mechanism
  • NAD+ for supporting mitochondrial function at the cofactor level while MOTS-c handles signaling
  • BPC-157 for recovery support when training volume increases due to improved capacity

Get Your BioStack →

Verified Literature & Trial Registry · NCBI PubMed & ClinicalTrials.gov

MOTS-c: Indexed Studies & Clinical Trials

250 PubMed Publications Indexed

Evidence & Scope Notice (R06): The records below are retrieved directly from NCBI PubMed and ClinicalTrials.gov. Preclinical (rodent/in vitro) studies do not establish human safety or efficacy. This index is for educational research literacy only and is never medical advice.

Registered Human Clinical Trials (ClinicalTrials.gov)

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

Conditions: Diabetes, Clopidogrel Resistance, Amyloid

Primary Endpoint: mots-c predicts cardiovascular mortality in diabetic with coronary artery disease

Enrollment: N=120View NCT Record →
NCT06133946 ↗ACTIVE NOT RECRUITING

Cohort Of DEafness-gene Screening

Conditions: Hearing Loss

Primary Endpoint: Diagnosis of hearing loss at age of 3 months

Enrollment: N=35,920View NCT Record →
NCT03878706 ↗RECRUITING

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Conditions: Diabetes Mellitus, Type 2

Primary Endpoint: Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.

Enrollment: N=240View NCT Record →
NCT07678073 ↗NARECRUITING

Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation

Conditions: Kidney Disease, End-Stage, Kidney Transplant, Kidney

Primary Endpoint: Serum ferroptosis-related biomarkers (Fe, TFRC1, GPX4, MDA, ACSL4) and mitochondrial-derived peptides (humanin and MOTS-c)

Enrollment: N=68View NCT Record →
NCT07505745 ↗PHASE2RECRUITING

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

Conditions: Prediabetes, Insulin Resistance, Overweight/Obesity

Primary Endpoint: Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index)

Enrollment: N=120View NCT Record →

Selected Peer-Reviewed PubMed Literature

PMID: 25738459 ↗2015 Mar 3· Cell metabolism

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Lee C, Zeng J, Drew BG et al. · DOI: 10.1016/j.cmet.2015.02.009

PMID: 36824008 ↗2023 May· Diabetes & metabolism journal

Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases

Kong BS, Lee C, Cho YM · DOI: 10.4093/dmj.2022.0333

PMID: 36761202 ↗2023· Frontiers in endocrinology

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

Zheng Y, Wei Z, Wang T · DOI: 10.3389/fendo.2023.1120533

PMID: 34798268 ↗2022 Jan· Pharmacological research

The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus

Yin Y, Pan Y, He J et al. · DOI: 10.1016/j.phrs.2021.105987

PMID: 33473109 ↗2021 Jan 20· Nature communications

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Reynolds JC, Lai RW, Woodhead JST et al. · DOI: 10.1038/s41467-020-20790-0

PMID: 36233287 ↗2022 Oct 9· International journal of molecular sciences

MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases

Mohtashami Z, Singh MK, Salimiaghdam N et al. · DOI: 10.3390/ijms231911991